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OBJECTIVE: The goal of the present study was to compare the prognoses of patients with non-ST-elevation
acute coronary syndromes who were treated with invasive or conservative treatment strategies.
METHODS: We performed a meta-analysis of studies of patients with non-ST-elevation acute coronary
syndromes to assess the benefits of an invasive strategy vs. a conservative strategy for short- and long-term
survival. We searched PubMed for studies published from 1990 to November 2012 that investigated the effects
of an invasive vs. conservative strategy in patients with non-ST-elevation acute coronary syndromes. The
following search terms were used: ‘‘non-ST-elevation myocardial infarction’’, ‘‘unstable angina’’, ‘‘acute
coronary syndromes’’, ‘‘invasive strategy’’, and ‘‘conservative strategy’’. The primary endpoints were all-cause
mortality at 30 days and 1 year.
RESULTS: Seven published studies were included in the present meta-analysis. The pooled analyses show that an
invasive strategy decreased the risk of death (risk ratio [0.839] [95% confidence interval {0.648-1.086}; I2,
86.46%] compared to a conservative strategy over a 30-day-period. Furthermore, invasive treatment also
decreased patient mortality (risk ratio [0.276] [95% confidence interval {0.259-0.294}; I2, 94.58%]) compared to
a conservative strategy for one year.
CONCLUSION: In non-ST-elevation acute coronary syndromes, an invasive strategy is comparable to a
conservative strategy for decreasing short- and long-term mortality rates.
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& INTRODUCTION
Non-ST-elevation acute coronary syndrome (NSTE-ACS)
includes non-ST-elevation myocardial infarction (NSTEMI)
and unstable angina (UA), which accounted for more than
two thirds of all cases of acute coronary syndrome (ACS) in
the United States in 2009 (1). Furthermore, cardiovascular
disease, including NSTE-ACS, still remains the leading
cause of mortality worldwide (2). NSTE-ACS represents
an increasingly frequent cause of hospital admission,
as it is the most frequent presentation of coronary instabi-
lity in patients with prior cardiac events or coronary
revascularizations (3). Compared with ST-elevation myo-
cardial infarction (STEMI), NSTE-ACS is usually associated
with a partial or transient coronary obstruction that results
in a temporary reduction in coronary blood flow, and
microemboli have also been implicated in the pathophysiol-
ogy of NSTE-ACS (4). Recognizing the difference between
NSTE-ACS and STEMI is critical when developing ther-
apeutic strategies for NSTE-ACS. For instance, thrombolytic
management is not indicated in NSTE-ACS management
(5). Experimental data from randomized clinical trials have
clearly demonstrated the efficacy of conservative or invasive
approaches in the above mentioned patients (6-8). In clinical
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practice, physicians caring for NSTE-ACS patients are
faced with immediate decisions about substantially differ-
ent therapeutic strategies that may significantly affect short-
and long-term outcomes (9).
An increasing number of studies have demonstrated that
an invasive treatment strategy rather than a conservative
approach improves the outcomes of NSTE-ACS patients
(6-8,10-16). However, some studies have shown that a
conservative strategy provides the same benefit as an
invasive strategy for NSTE-ACS patients, and clearly shown
that the efficacy of invasive treatment was not definite
(17,18).
According to the 2012 American College of Cardiology
Foundation/American Heart Association Task Force on
practice guidelines (19), medical therapy remains a corner-
stone in managing patients with NSTE-ACS, and we found
that in the above mentioned studies that demonstrated the
benefit of an invasive strategy, the administration of
antithrombotics (antiplatelets or oral anticoagulants) statins
was the primary step prior to interventional therapy.
However, in the conservative treatment group, the NSTE-
ACS patients also received interventional therapy during
the index hospitalization when medical therapy failed or if
substantial residual ischemia was documented in some of
the randomized control trials (RCTs) (6,8,9,18,20,21).
It is necessary to clearly distinguish between the different
efficacies for invasive and conservative strategies for NSTE-
ACS patients. Therefore, we performed the present meta-
analysis to analyze the benefits between invasive and
conservative strategies for NSTE-ACS patients.
& METHODS
We followed the Preferred Reporting Items for Systematic
reviews and Meta-Analysis (PRISMA) guidelines (22) for
randomized clinical trials and the Meta-analysis Of
Observational Studies in Epidemiology (MOOSE) guide-
lines (23) for observational cohort studies in the present
meta-analysis.
Study search strategy
Accessing the PubMed database, we conducted a litera-
ture search for research papers published from 1990 to
November 2012. The following search terms and keywords
were used: ‘‘non-ST-elevation myocardial infarction’’,
‘‘unstable angina’’, ‘‘acute coronary syndromes’’, ‘‘invasive
strategy’’, and ‘‘conservative strategy’’. In addition, we also
manually checked the reference list of each article. The main
focus of the study was RCTs and observational cohort
studies (OCS). We excluded those research papers with the
following keywords: ‘‘review’’, ‘‘review literature’’, ‘‘review
of reported cases’’, ‘‘review, academic’’, ‘‘review, multi-
case’’, ‘‘review, tutorial’’, ‘‘case reports’’, ‘‘congresses’’,
‘‘interview’’, ‘‘overall’’, ‘‘comment’’, ‘‘letter’’, ‘‘practice
guideline’’, ‘‘scientific integrity review’’, ‘‘news’’, ‘‘news-
paper article’’, and ‘‘address’’. The search was limited by
the search words of ‘‘.19 years’’, ‘‘Publication Date from
1990/01/01 to 2012/11/01’’, ‘‘English’’, and ‘‘Human’’.
Study Selection
Eligible patients had experienced NSTE-ACS (i.e.,
NSTEMI or UA) that was treated with invasive or
conservative treatment during the admission. The NSTE-
ACS diagnosis was based on the American College of
Cardiology Foundation/American Heart Association
(ACCF/AHA) Guidelines 2012 for NSTE-ACS (19). In our
present meta-analysis, the invasive group contained
patients who underwent cardiac catheterization, diagnostic
angiography, coronary artery bypass graft (CABG) surgery,
and intra-aortic balloon pump (IABP) performed during the
index hospitalization with or without revascularization; the
conservative group contained patients who did not undergo
catheterization, angiography, CABG, or IABP during the
index hospitalization. Conservative therapy consists of
vigorous anti-ischemic therapy with nitrates, statins, b-
blockers, and (sometimes) calcium channel blockers, as well
as antithrombotic therapy with aspirin, clopidogrel, or
ticagrelor, and low molecular weight heparin (LMWH)
while the patients are in the hospital. In ACS patients,
antithrombotics can effectively inhibit thrombus formation
and coagulation, and stains can play important roles in
stabilizing plaque, inhibiting vascular endothelial inflam-
mation, improving endothelial function, and reducing
cholesterol levels. The main endpoints were death from all
causes at 30 days and 1 year. Patients who received both
conservative and interventional therapy in the hospital were
excluded.
We originally planned to perform the meta-analysis in
two parts: RCTs and OCS analyzed in two separate meta-
analyses; however, there was only one RCT included in the
present work (17). For this reason, we retrospectively
Table 1 - Characteristics of the included NSTE-ACS studies.
Sources Study Design
Number of Deaths/
Patients who
Underwent Invasive
Treatment for
30 days
Number of Deaths/
Patients who
Underwent
Conservative
Treatment for 30 days
Number of Deaths/
Patients who
Underwent Invasive
Treatment for
1 year
Number of Deaths/
Patients who Underwent
Conservative Treatment
for 1 year
OCS
Leslie et al., (11) 2003*g Retrospective 100/4535 97/3362 181/4535 309/3362
Timm et al., (12) 2007g Prospective 101/945 227/815
Cindy et al., (13) 2008g Prospective 55/1382 82/754
Roge´rio et al., (14) 2009*g Prospective 1/386 13/334 16/386 46/334
Kouraki et al., (15) 2011g Prospective 98/1215 185/771
Joakim et al., (16) 2011g Prospective 814/28112 2381/18343
RCTs
William et al., (17) 1998*g RCT 33/442 7/256 52/442 24/256
NSTE-ACS: non-ST-elevation acute coronary syndrome; RCT: randomized controlled trials. * Included in the meta-analysis of all-cause mortality within 30
days for patients with NSTE-ACS. g The seven studies included in the meta-analysis of all-cause mortality within 1 year for NSTE-ACS patients.
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analyzed all included studies at two different time points
(30 days and 1 year) by meta-analysis.
Data Extraction
In addition to information about the study design,
characteristics, and sample size, we extracted the following
data from the research papers: the actual number of
survivors and non-survivors and corresponding cohort
sizes. The main outcome variables were 30-day and 1-year
survival rates.
Statistical Analysis
We performed the meta-analysis using Comprehensive
Meta-analysis software, version 2.2.064 (Biostat, Englewood,
NJ, USA). Risk ratios (RR) and 95% confidence intervals
(95% CI) were calculated for each study and pooled with a
random effects model because the heterogeneity of all meta-
analyses could not be ignored, as indicated by an I2 statistics
above 50% and a p,0.10. Heterogeneity among studies was
formally assessed by the Q and I2 statistics. Publication bias
was assessed by calculating the fail-safe number (Nfs) (24)
according to the formula Nfs.05 = (SZ/1.645)2-N. A fail-
safe number indicates the number of non-significant,
unpublished studies that would need to be added to a
meta-analysis to reduce the overall statistically significant
results to non-significance. If the number is large relative to
the number of observed studies, the summary conclusions
are fairly reliable. All analyses were performed using the
SPSS 17.0 software package (SPSS, Inc., Chicago, IL, USA),
and p-values,0.05 were considered to be statistically
significant.
& RESULTS
Seven studies were included in the meta-analysis; one
study was an RCT, and the other six were OCS; the total
number of patients in all seven studies was 61,652 (11-17)
(Figure 1) (Table 1).
There were three studies in the first meta-analysis
(11,14,17); we used all-cause mortality at 30 days as the
primary endpoint, and 9,315 patients were included in the
systematic review. After the data were analyzed, we found
that an invasive strategy was associated with a statistically
significant 15.6% decreased mortality (RR, 0.839 [95% CI,
0.648-1.086]) compared to conservative strategy during the 30
days after hospital discharge (Figure 2). In this meta-analysis,
Figure 1 - Study selection process for the studies included in the Meta-Analysis (based on the PRIMA guidelines).
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we used a random-effects model to consider the effect of
heterogeneity among the studies (Q= 14.77, p= 0.001,
I2 = 86.46%). The calculation for the Nfs.05 is 20.97, which
suggests that there need to be 21 studies with a negative
conclusion to reverse the conclusion. The conclusion from this
meta-analysis is convincing, with little risk of publication bias.
In the next systematic review, the seven studies were
included in the meta-analysis. We compared the mortality
of patients treated with an invasive strategy and a
conservative strategy for one year after hospital discharge.
Of the 37,017 patients with NSTE-ACS who received
invasive treatments and were discharged, there were 1,317
patients who died within one year. However, 24,635
patients received conservative treatment and were dis-
charged and 3,254 patients died within one year. After the
data were pooled, we found that invasive therapy sig-
nificantly reduced mortality by 73.1% within one year after
discharge (RR, 0.276 [95% CI, 0.259-0.294]) compared to
conservative therapy (Figure 3). In the second meta-
analysis, we also used a random-effects model to consider
the effect of heterogeneity among the studies (Q= 110.7,
p,0.001, I2 = 94.58%). The sensitivity analysis reveals that
2,505 negative studies have been missed to reverse the
statistical significance (Nfs.05 = 2505). The conclusion from
the second meta-analysis is convincing, and the publication
bias could be neglected.
& DISCUSSION
NSTE-ACS is responsible for approximately 1 million
admissions to U.S. hospitals and twice as many to European
hospitals each year and is associated with an in-hospital
mortality rate of approximately 5% (25). Worldwide, more
than 4 million people each year are estimated to have a
NSTEMI, and long-term mortality is higher in patients with
NSTE-ACS than in those with ST-elevation acute coronary
syndrome (STE-ACS) (26,27). In 2012, the ACCF/AHA
published an update to their 2011 guidelines for the
management of patients with NSTE-ACS (19,28).
According to the new guidelines, selecting either invasive
or conservative strategy is one of the most important
decisions that must be made in managing NSTE-ACS
patients. The ACC/AHA guidelines continue to support
an early invasive strategy in patients with high-risk NSTE-
ACS without serious comorbidities or contraindications to
angiography; in contrast, an early conservative approach
should be selected for low-risk patients.
The results of our present study were consistent with the
new 2012 guidelines, and the two systematic meta-analyses
showed that compared to a conservative strategy, an
invasive strategy is associated with reduced short- and
long-term mortality in patients with NSTE-ACS after
hospital discharge.
Figure 2 - Primary analysis of the OCS in NSTE-ACS within 30 days.
Figure 3 - Primary analysis of the NSTE-ACS OCS within 1 year.
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Meta-analyses are statistical tools for pooling existing
evidence; therefore, we considered the strength of the
evidence from all seven studies (11-17). We searched and
analyzed those articles addressing the treatment strategies
for NSTE-ACS. Furthermore, we studied the details of the
related studies according to the 2012 guidelines (19); these
studies include well-known studies such as the FRISC II
(Fragmin and Fast Revascularization During Instability in
Coronary Artery Disease II) (4), the RITA 3 (Randomized
Intervention Trial of Unstable Angina 3) trial (8), TACTICS-
TIMI 18 (Treat angina with Aggrastat and Determine Cost of
Therapy with an Invasive or Conservative Strategy-
Thrombolysis in Myocardial Infarction 18) trial (7), ICTUS
(Invasive vs Conservative Treatment in Unstable Coronary
Syndromes) trial (29), TIMI IIIB (Thrombolysis in
Myocardial Infarction IIIB) (30), MATE (Medicine vs
Angiography in Thrombolytic Exclusion) (31), and VINO
(Value of First Day Angiography/Angioplasty In Evolving
Non-ST Segment Elevation Myocardial Infarction) (32).
Based on the above mentioned studies, we found that an
invasive strategy could improve the short- or long-term
survival rates of NSTE-ACS patients compared to a
conservative strategy. In addition, a related meta-analysis
demonstrated that an invasive strategy had comparable
benefits in men and high-risk women for reducing the
composite end point of death, MI, or re-hospitalization with
NSTE-ACS (33).
In our present work, we did not distinguish between
gender, age, risk factors, and complications for the two
strategies; however, we focused on the all-cause mortality at
30 days and 1 year after hospital discharge. At the same
time, we strictly limited the definition of the invasive and
conservative strategies. The invasive group contained
patients who underwent cardiac catheterization during the
index hospitalization with or without revascularization; in
contrast, patients who did not receive catheterization in the
hospital were included in the conservative group.
Catheterization included angiography and percutaneous
coronary intervention; moreover, patients who underwent
CABG surgery and IABP in the hospital were included in
the invasive group. Our purpose was to assess whether a
particular strategy decreased all-cause mortality in NSTE-
ACS patients. Boden et al. (17) demonstrated that some
NSTE-ACS patients in the conservative group also received
interventional therapy, but we analyzed the total details of
the study and regrouped the patients into the conservative
or invasive management groups; then, we retrospectively
analyzed the data and eliminated the interference from the
two therapies with one another. Although the William et al.
study was a RCT, we included it in the present work after
addressing the interfering factors. Thus, seven studies were
included in our meta-analysis.
While analyzing our data, we assessed other reviews that
compared the effectiveness of both strategies in NSTE-ACS
patients. These reviews include Nu´n˜ez et al. (9), Boden
(34,35), Neumann et al. (36), Choudhry et al. (37),
O9Donoghue et al. (33), Hoenig et al. (38,39), Navarese
et al. (40), and Damman P et al. (41) Based on these reviews,
we found that over the past 10 years, there is still
controversy regarding invasive versus conservative strategy
in NSTE-ACS patients. Compared with a conservative
strategy for NSTE-ACS patients, some studies reported that
an invasive therapy provided comparable benefits and
reduced the rates of fatal or nonfatal re-infarction and
hospital readmission but not all-cause mortality (9,33,35,37).
However, other studies found that an invasive strategy was
not related to improvements in long-term survival and
reduced the rate of revascularization compared with
conservative management (34,36,40,41).
Furthermore, the above mentioned studies did not strictly
distinguish between or define conservative and invasive
strategies; for instance, the administration of antithrombo-
tics was the primary step prior to interventional therapy in
invasive strategy. However, in some RCTs, patients with
NSTE-ACS in the conservative treatment group also
received interventional therapy during the index hospitali-
zation when medical therapy failed or if substantial residual
ischemia was documented. Based on these facts, we defined
the concept of conservative and invasive strategies strictly
as described in our article and performed the meta-analysis
based on these definitions.
Inspired by the above mentioned studies, we strictly
redefined the conservative and invasive strategy and retro-
spectively analyzed seven studies. The NSTE-ACS patients
who received interventional management in the hospital
were included in the invasive group, whereas the other
patients were placed in the conservative group. The main
end-point events were 30-day and 1-year all-cause mortal-
ity. After performing two systematic meta-analyses, we
found that invasive therapy improved the prognosis of
patients with NSTE-ACS (compared with conservative
therapy) and reduced the short- and long-term mortality.
We also noted that the results of the Boden et al. study
(17) demonstrated that conservative therapies could play
more beneficial roles in NSTE-ACS patients than did
invasive strategies. What are the reasons for the opposite
results? We analyzed their findings in detail and further
studied its quotation from Ferry et al. (42) and found that
the authors excluded 247 patients with high-risk ischemic
complications (e.g., unstable angina after infarction, con-
gestive heart failure that did not respond to medical
therapy, cardiogenic shock, or symptomatic ventricular
arrhythmia) during the first 48 hours after the onset of
infarction. Moreover, the invasive theories, techniques and
equipment were not then as well established as they are
currently. With the development of modern percutaneous
coronary intervention technology, invasive strategies show
more benefit than conservative medical therapies in NSTE-
ACS patients.
For patients with NSTE-ACS (NSTEMI/UA), an invasive
strategy reduces short- and long-term all-cause mortality
compared with a conservative strategy. An invasive strategy
is preferable to a conservative strategy in treating NSTE-
ACS. Of course, these results require validation in future
RCTs.
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